This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults.
Attention deficit hyperactivity disorder: diagnosis and management it aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
In April 2018, we made clarifications to recommendations 1.5.10, 1.5.12, 1.5.13, 1.7.4, 1.7.7 and 1.8.14 and their rationale and impact sections. A footnote about the marketing authorisation for methylphenidate was also added to recommendation 1.7.11.
This guideline includes new and updated recommendations on:
- information and support
- managing ADHD
- medication, including monitoring and review
- adherence to treatment
It also includes recommendations on:
Who is it for?
- Healthcare professionals
- Commissioners and providers
- People with ADHD, and their families and carers